University of Regensburg

Granite Bio Emerges with $100M Funding and Novel Immunology Pipeline for IBD and Allergies

a month ago

• Versant Ventures has launched Granite Bio with $100 million in funding, advancing two novel antibody drugs targeting inflammatory conditions through its Ridgeline Therapeutics initiative. • Granite's lead candidate GRT-001 targets pro-inflammatory monocytes in IBD and is currently in Phase 1 trials, with ulcerative colitis studies planned for later this year. • The company's second candidate, GRT-002, targets IL-3 for treating itch and allergies, representing a different approach from established therapies like Dupixent and Cosentyx.